Skip Navigation

Stem Cell Transplant Clinical Research and Trials

  • Cell Manipulation Core

    We are committed to increasing access to stem cell transplant procedures, making it safer and more effective for patients, reducing transplant-related complications and improving immune system recovery.

    Our stem cell transplant clinical trials are nationally recognized for major advances in cancer treatment as a result of our research, including:

    • Developing new drugs to prevent or help manage graft-versus-host disease (GVHD). Graft-versus-host disease (GVHD): a common and potentially severe side effect of stem cell transplants in which donor immune cells attack healthy patient cells and tissues.
    • Using cord blood transplant to increase treatment options for patients without other suitable matched donors
    • Developing cancer vaccine strategies for use along with transplant to stimulate the graft-versus-leukemia (GVL) effect and minimize disease relapse. Graft-versus-leukemia (GVL) effect: a therapeutic effect in which transplanted immune cells attack residual leukemia or other tumor cells.

    We're also home to the Connell and O'Reilly Families Cell Manipulation Core Facility, which is New England's only state-of-the-art cell manipulation facility. This facility processes hematopoietic stem cells for transplant, generate modified tumor cells as therapeutic vaccines, and prepare immune cell populations for adoptive therapy.

    Learn about current stem cell transplant clinical trials at Dana-Farber/Brigham and Women's Cancer Center

  • Dana-Farber/Brigham and Women's Cencer Center logo
    US News Best Hospitals badge 2016-2017

    Appointments and Second Opinions
    877-442-3324

    Make Appointment Online

  • David Weinstock, MD, discusses his work with stem cell transplant patients, and describes how Dana-Farber rapidly translates laboratory discoveries to patient treatments